Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four opioid analgesics—codeine, oxycodone, IRcodone (no recognized pharmaceutical agent by this name), and tramadol. Codeine and oxycodone are classic opioids that act primarily as mu-opioid receptor agonists to provide analgesia for moderate to severe pain. Tramadol is a synthetic opioid with dual mechanisms of action; it acts as a weak mu-opioid receptor agonist and also inhibits the reuptake of serotonin and norepinephrine, contributing to its analgesic effects[1][3][4][5]. The combination would theoretically provide multimodal pain relief but significantly increases the risk for additive central nervous system depression, respiratory depression, overdose, dependence, and other serious adverse effects[2][7]. There is no evidence that such a four-drug combination exists as an approved or marketed product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine + oxycodone + IRcodone + tramadol.